TY - JOUR AU - Basappa, Naveen S. PY - 2016/12/15 Y2 - 2024/03/28 TI - Treatment options in advanced renal cell carcinoma after first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors JF - Canadian Urological Association Journal JA - CUAJ VL - 10 IS - 11-12 SE - Supplement-Review DO - 10.5489/cuaj.4292 UR - https://cuaj.ca/index.php/journal/article/view/4292 SP - S242-4 AB - <p class="body1">Targeted therapy for metastatic renal cell carcinoma (mRCC) was introduced a decade ago, and since then a number of therapeutic options have been developed. Vascular endothelial growth factor targeted therapy is the widely accepted first-line option for mRCC. After progression, treatment in the second-line setting has typically been with either axitinib or everolimus. However, with the advent of several new agents demonstrating efficacy in the second-line setting, including nivolumab, cabozantinib, and the combination of lenvatinib and everolimus, the treatment paradigm has shifted toward these novel therapies with improved patient outcomes.</p> ER -